Lab-grown islets for transplant
Seraxis Islets mimic native islets from a human pancreas
Seraxis has effectively produced islets which are identical to native pancreas islets.
Seraxis Islets secrete insulin and glucagon like a native islet
Biphasic response to glucose demonstrates Seraxis islets have mature islet molecular machinery
Seraxis islets respond to Tolbutamide and Diazoxide the same way a native pancreas does. These are two common drugs that are administered to diabetics to regulate insulin secretion.
Reliable production of stem cell-derived islets
- Large-scale manufacturing yields reproducible, consistent batches of islets at 95-100% purity
- No cell sorting or selection necessary
- Clusters contain 60-90% insulin-secreting beta cells
- No use of viruses, no integrating plasmid
- Never exposed to serum or any animal products
- Favorable risk:benefit ratio due to lack of tumorigenicity and high potency
Seraxis islets are derived from an immortal “iPS-variant” line that was created by Seraxis from a human islet. This line is proprietary, patented, and stored as a cGMP compliant master cell bank.
Unique source of human islets
Unlike Seraxis, no group has ever published
- reliable production of stem cell-derived islets at more than 30% purity without physical non-scalable selection of individual cells
- production of pure islets (with insulin, glucagon, and the other pancreatic hormones) from stem cells that is not contaminated by non-pancreatic cells
- consistent production of pure, high-potency islets from stem cells (embryonic stem or iPS cells) in scalable, large-format closed culture systems
- achieving these goals without the use of serum, animal products, and other non-defined reagents